The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IBC 2025 | The potential for early interception in MBL: advances and barriers
Anton Langerak, PhD, Erasmus MC, Rotterdam, The Netherlands, comments on the potential of early intervention for patients with monoclonal B-cell lymphocytosis (MBL). Dr Langerak notes that while there is potential, it is still early days and more research is needed to understand the genetic and protein landscape of early-stage MBL. This interview took place at the 3rd Intercepting Blood Cancers (IBC) Workshop held in Nice, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Based on the data that we have obtained, I think it’s too early days for that, for a couple of reasons. We’re just starting to understand what a different genetic and protein landscape is in those early stages. And I think what we need to do is clearly define the ones that are really at high risk of developing progression into CLL or lymphoma for that matter...
Based on the data that we have obtained, I think it’s too early days for that, for a couple of reasons. We’re just starting to understand what a different genetic and protein landscape is in those early stages. And I think what we need to do is clearly define the ones that are really at high risk of developing progression into CLL or lymphoma for that matter. So I think based on what I’ve shown, yes, there could be potential for thinking that direction. But then really if we use those data for defining high-risk groups. But still, I think in MBL, as opposed to, for example, in myeloma, smoldering myeloma, or maybe even with CCUS, I think it’s a bit difficult to see how this would evolve knowing that the aggressiveness of the disease is different, such that it will take longer before it finally develops into a malignancy. And so, yeah, there’s another balance to be taken there or consideration to be made on the anxiety of starting to treat versus the benefit of that treatment.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
